GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (NAS:AGIO) » Definitions » EBITDA per Share

AGIO (Agios Pharmaceuticals) EBITDA per Share : $-7.28 (TTM As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Agios Pharmaceuticals EBITDA per Share?

Agios Pharmaceuticals's EBITDA per Share for the three months ended in Dec. 2024 was $-2.10. Its EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-7.28.

During the past 3 years, the average EBITDA per Share Growth Rate was -5.90% per year. During the past 5 years, the average EBITDA per Share Growth Rate was -8.90% per year. During the past 10 years, the average EBITDA per Share Growth Rate was -11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Agios Pharmaceuticals's EBITDA per Share or its related term are showing as below:

AGIO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -62.7   Med: -13.5   Max: 11.2
Current: -5.9

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Agios Pharmaceuticals was 11.20% per year. The lowest was -62.70% per year. And the median was -13.50% per year.

AGIO's 3-Year EBITDA Growth Rate is ranked worse than
67.97% of 1224 companies
in the Biotechnology industry
Industry Median: 10.3 vs AGIO: -5.90

Agios Pharmaceuticals's EBITDA for the three months ended in Dec. 2024 was $-123.67 Mil.

During the past 3 years, the average EBITDA Growth Rate was -4.40% per year. During the past 5 years, the average EBITDA Growth Rate was -6.10% per year. During the past 10 years, the average EBITDA Growth Rate was -17.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Agios Pharmaceuticals was -1.20% per year. The lowest was -81.30% per year. And the median was -16.40% per year.


Agios Pharmaceuticals EBITDA per Share Historical Data

The historical data trend for Agios Pharmaceuticals's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals EBITDA per Share Chart

Agios Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.73 -6.11 -6.95 -6.92 -7.26

Agios Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.88 -1.61 -1.84 -1.74 -2.10

Agios Pharmaceuticals EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Agios Pharmaceuticals's EBITDA per Share for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA per Share(A: Dec. 2024 )
=EBITDA/Shares Outstanding (Diluted Average)
=-420.084/57.889
=-7.26

Agios Pharmaceuticals's EBITDA per Share for the quarter that ended in Dec. 2024 is calculated as

EBITDA per Share(Q: Dec. 2024 )
=EBITDA/Shares Outstanding (Diluted Average)
=-123.67/58.813
=-2.10

EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Agios Pharmaceuticals  (NAS:AGIO) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Agios Pharmaceuticals EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Agios Pharmaceuticals Business Description

Traded in Other Exchanges
Address
88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Executives
Jacqualyn A Fouse director C/O DICK'S SPORTING GOODS, 345 COURT STREET, CORAOPOLIS PA 15108
Tsveta Milanova officer: Chief Commercial Officer C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY SREET, CAMBRIDGE MA 02139
James William Burns officer: Chief Legal Officer C/O AGIOS PHARMACEUTICALS, 88 SIDNEY STREET, CAMBRIDGE MA 02139
Washburn Theodore James Jr. officer: Principal Accounting Officer C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
David Scadden director 88 SIDNEY STREET, CAMBRIDGE MA 02139
Rahul D. Ballal director 116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Cecilia Jones officer: Chief Financial Officer C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Brian Goff director, officer: Chief Executive Officer C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Sarah Gheuens officer: Chief Medical Officer C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Kaye I Foster-cheek director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
David P Schenkein director, 10 percent owner, officer: Chief Executive Officer C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Catherine E. Owen director 1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Jeffrey D Capello director C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Richa Poddar officer: Chief Commercial Officer C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139